SCHEMBL2607007

SCHEMBL2607007

CCN(C)CCC(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM5A P29375 3/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
HDAC6 Q9UBN7 3/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.31
STING1 Q86WV6 1/20 0.31
EPHX2 P34913 1/20 0.31
CYP2D6 P10635 1/20 0.30
DNM1 Q05193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18195632 0.89 KDM5A (0.40) MEN1KMT2AKDM5ACA12CA1
SCHEMBL14237883 0.88 KMT2A (0.54) MEN1KMT2AKDM5ACA12CA1
SCHEMBL25634868 0.87 KDM5A (0.46) MEN1KMT2AKDM5ACA12CA1
SCHEMBL12009412 0.83 MEN1 (0.41) MEN1KMT2AKDM5AKDM4CDNM1
SCHEMBL18195629 0.82 MEN1 (0.36) MEN1KMT2ACA12CA1CA7
SCHEMBL2606995 0.81 MEN1 (0.40) MEN1KMT2ACA12CA1CA7
SCHEMBL949184 0.81 L3MBTL1 (0.35) MEN1KMT2ACA12CA1CA7
SCHEMBL9199990 0.79 KMT2A (0.37) MEN1KMT2ACA12CA1CA7
SCHEMBL23546635 0.78 CA12 (0.34) MEN1KMT2ACA12CA1CA7
SCHEMBL21335943 0.78 MEN1 (0.48) MEN1KMT2AKDM5ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11013696-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2021-05-25 US disclosed
US-20190321295-A1 Method of Encapsulating a Nucleic Acid in a Lipid Nanoparticle Host NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2019-10-24 US disclosed
US-10342761-B2 Method of encapsulating a nucleic acid in a lipid nanoparticle host NOVARTIS AG (CH) 2019-07-09 US disclosed
US-20170196809-A1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2017-07-13 US disclosed
US-20170196809-A1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2017-07-13 US disclosed
US-20160317458-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2016-11-03 US disclosed
EP-1730152-B1 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORP (JP) 2012-05-02 EP disclosed
US-8158640-B2 Tetrahydroquinoline derivatives and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-17 US disclosed
US-8158640-B2 Tetrahydroquinoline derivatives and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-17 US disclosed
US-20110039828-A1 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-17 US disclosed
US-20110039828-A1 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-17 US disclosed
US-7872126-B2 Tetrahydroquinoline derivatives and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-01-18 US disclosed
US-7872126-B2 Tetrahydroquinoline derivatives and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-01-18 US disclosed
US-20070082896-A1 Tetrahydroquinoline derivatives and a process for preparing the same TANABE SEIYAKU CO., LTD. 2007-04-12 US disclosed
US-20070082896-A1 Tetrahydroquinoline derivatives and a process for preparing the same TANABE SEIYAKU CO., LTD. 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190321295-A1 Method of Encapsulating a Nucleic Acid in a Lipid Nanoparticle Host POLN, POLRMT, RNGTT MEN1 3053/4885KMT2A 3594/4885KDM5A 4854/4885
US-20170196809-A1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST POLN, POLRMT, RNGTT MEN1 3053/4885KMT2A 3594/4885KDM5A 4854/4885
US-20070082896-A1 Tetrahydroquinoline derivatives and a process for preparing the same CETP, MTTP, NPC1L1 MEN1 3015/4885KMT2A 2623/4885KDM5A 3013/4885
US-20160317458-A1 Lipids and Lipid Compositions for the Delivery of Active Agents SGMS1, PHOSPHO1, LIPA MEN1 553/4885KMT2A 3563/4885KDM5A 4760/4885
US-10342761-B2 Method of encapsulating a nucleic acid in a lipid nanoparticle host POLN, POLRMT, RNGTT MEN1 3053/4885KMT2A 3594/4885KDM5A 4854/4885
US-11013696-B2 Lipids and lipid compositions for the delivery of active agents PHOSPHO1, SGMS1, LIPA MEN1 591/4885KMT2A 3560/4885KDM5A 4753/4885
US-20110039828-A1 TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME CETP, MTTP, NPC1L1 MEN1 3015/4885KMT2A 2623/4885KDM5A 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.